



## Medicine: sotorasib (brand name: Lumykras®)

Amgen Ltd

The Scottish Medicines Consortium (SMC) has assessed sotorasib for the treatment of adult patients with non-small cell lung cancer (NSCLC), where the cancer is locally advanced or metastatic (has spread to tissues near the lung or to other parts of the body) and the cancer cells have an abnormal gene called KRAS G12C. It is for use when the patient's cancer has got worse after treatment with platinum-based chemotherapy or immunotherapy (that targets PD-1 or PD-L1), or both, or where the patient could not tolerate these treatments. This document summarises the SMC decision and what it means for patients.

### What has SMC said?

After careful consideration, SMC has accepted sotorasib on an interim basis (interim acceptance), for the treatment of NSCLC, as described above. Interim acceptance is an option available to SMC for certain\* medicines. In this case, the clinical evidence in the company submission was based on a single-arm clinical trial, which means there is no comparison with placebo or another treatment, leading to uncertainty in the evidence for decision making. An interim acceptance means that sotorasib is accepted for use subject to ongoing evaluation and reassessment once further evidence is available.

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of sotorasib. In addition, SMC was able to apply a more flexible approach\*\* in the assessment, as it is for a rare condition where patients are likely to have a life expectancy of less than three years with currently available treatments.

### What does SMC's decision mean for patients?

The decision to accept sotorasib on an interim basis means that if your healthcare professional thinks that it is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. Once further evidence is available, SMC will reassess the medicine and provide an updated decision on its routine availability in NHSScotland.



### What is sotorasib used for?

Sotorasib is used for the treatment of adult patients with a type of lung cancer called NSCLC. It is for treating NSCLC that is locally advanced or metastatic, where the cancer cells have an abnormal gene called KRAS G12C. This occurs in around 13% of NSCLC cases and is associated with a poor prognosis.

\*<https://www.scottishmedicines.org.uk/how-we-decide/interim-acceptance-decision-option/>

\*\*<https://www.scottishmedicines.org.uk/how-we-decide/pace/>

## How does sotorasib work?

The KRAS G12C gene makes an abnormal KRAS protein. This abnormal protein is overactive and causes the cells to grow in an uncontrolled way. Sotorasib blocks the KRAS protein which may help to slow down the growth of the cancer cells.

## How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of sotorasib by looking at the SMC Detailed Advice Document (SMC2443).

## More information

The organisations below can provide more information and support for people with lung cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

### Roy Castle Lung Cancer Foundation



<https://www.roycastle.org>



0333 323 7200

### Scottish Lung Cancer Nurses Forum – affiliated to Lung Cancer Nursing UK



<https://www.lcnuk.org>



01675 477607

You can find out more about sotorasib (Lumykras®) in the Patient Leaflet by searching for the medicine name on the electronic medicines compendium (EMC) website.



<https://www.medicines.org.uk/emc/>